معرفی
Dennis Sgroi, MD serves as Executive Vice Chair of Pathology at Massachusetts General Hospital and Professor of Pathology at Harvard Medical School. He is a key faculty member of the Breast Pathology Service and affiliated with the Dana-Farber/Harvard Cancer Center's Breast Cancer and Cancer Genetics programs.
Dr. Sgroi earned his MD from University of Connecticut School of Medicine and completed both residency and fellowship training at Massachusetts General Hospital. He is board certified in Pathology - Anatomic - General by the American Board of Pathology.
His research focuses on Human Breast Cancer Anti-Hormonal Resistance, with particular expertise in biomarker development. His laboratory investigates the clinical utility of HOXB13:IL17BR and MGI biomarkers in estrogen receptor-positive, lymph node negative breast cancer patients, and examines the molecular functional role of HOXB13 and IL17BR in anti-hormonal therapeutic response.
Dr. Sgroi's publications reveal a consistent focus on breast cancer microenvironment and treatment resistance mechanisms. His work spans molecular pathology, tumor-stroma interactions, and translational cancer research with implications for personalized treatment approaches.
As part of the Massachusetts General Hospital Breast Pathology Service, he contributes to a program handling approximately 4,500 case accessions annually, with 3,400 representing in-house breast cases across various specimen types.
